CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results

CVRx (NASDAQ:CVRX) released its quarterly earnings results on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01, Zacks reports. CVRx had a negative return on equity of 99.32% and a negative net margin of 94.10%.The business had revenue of $14.77 million during the quarter, compared to analyst estimates of $14.49 million.

Here are the key takeaways from CVRx’s conference call:

• CVRx reported a strong Q1, with total revenue of $14.8 million (+20%), U.S. revenue of $13.7 million (+22%), an improved gross margin of 87%, and a slightly smaller net loss, signaling that prior investments are beginning to drive commercial results.
• The transition to Category I CPT codes is a major reimbursement win, but new Medicare Advantage rules and payer automation produced a March dip in 30‑day prior‑authorization approvals (Q1 rate 46%), creating a near‑term administrative headwind that may add variability to access and timing of revenue.
• The BENEFIT‑HF randomized trial is underway (first site activated, first patient enrolled) and, if successful, could expand the addressable market from ~339,000 to >980,000 patients (~$30 billion TAM), although regulatory and enrollment timelines extend over several years.
• Commercial execution is improving — U.S. territories increased to 56 and active implanting centers to 257, and management reports higher utilization at targeted centers driven by a program‑focused sales approach, supporting sustained U.S. growth.
• Management reaffirmed 2026 guidance (revenue $63–67M, gross margin 85–87%, operating expenses $103–107M) despite the Q1 beat, reflecting a cautious posture early in the year while monitoring reimbursement and trial rollout trends.

CVRx Stock Performance

NASDAQ CVRX opened at $6.92 on Tuesday. The firm has a market cap of $182.90 million, a price-to-earnings ratio of -3.38 and a beta of 0.90. The company has a quick ratio of 6.72, a current ratio of 7.63 and a debt-to-equity ratio of 1.26. The business has a 50-day moving average price of $8.01 and a 200-day moving average price of $8.00. CVRx has a twelve month low of $4.30 and a twelve month high of $11.30.

Insider Buying and Selling at CVRx

In other CVRx news, Director Mudit K. Jain acquired 46,800 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was purchased at an average price of $6.36 per share, with a total value of $297,648.00. Following the completion of the purchase, the director directly owned 980,183 shares in the company, valued at approximately $6,233,963.88. The trade was a 5.01% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 18.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CVRx

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of CVRx during the fourth quarter worth $79,000. Corient Private Wealth LLC bought a new position in shares of CVRx during the fourth quarter worth $81,000. XTX Topco Ltd bought a new position in shares of CVRx during the fourth quarter worth $90,000. Alliancebernstein L.P. boosted its position in shares of CVRx by 10.7% during the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock worth $142,000 after acquiring an additional 1,700 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of CVRx by 61.3% during the fourth quarter. Wells Fargo & Company MN now owns 20,266 shares of the company’s stock worth $144,000 after acquiring an additional 7,705 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

Trending Headlines about CVRx

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx beat Q1 revenue and EPS expectations, reporting revenue of $14.77 million versus $14.49 million expected and a loss of $0.50 per share versus a $0.51 estimate. The company also said U.S. growth remained strong, supporting the market-expansion narrative. CVRx Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Management raised visibility on 2026 revenue with guidance of $63 million to $67 million, slightly above the market’s implied midpoint, which suggests continued commercial momentum even as the company still operates at a loss. CVRx signals $63M-$67M 2026 revenue outlook as Category I CPT transition reshapes prior authorization dynamics
• Neutral Sentiment: The Q1 earnings call highlighted category and reimbursement changes, including the transition to Category I CPT coding, which may improve prior-authorization dynamics over time but also adds some near-term uncertainty. CVRx Inc (CVRX) Q1 2026 Earnings Call Highlights: Strong U.S. Growth and Market Expansion Potential
• Negative Sentiment: Despite the beat, CVRx remains unprofitable, posting a GAAP loss of $0.50 per share and maintaining a large negative margin profile, so investors may remain cautious about valuation and the pace of earnings improvement. CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates

Analysts Set New Price Targets

CVRX has been the subject of several recent research reports. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price target on shares of CVRx in a report on Tuesday, April 14th. Weiss Ratings lowered shares of CVRx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Finally, Cantor Fitzgerald upgraded shares of CVRx to a “strong-buy” rating in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, CVRx presently has an average rating of “Buy” and a consensus price target of $11.50.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.